 |
Panorama of Celltrion headquarters. (Photo=Celltrion) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Celltrion's autoimmune disease treatment Remsima SC (US sales name "ZYMFENTRA") has been launched in the US market and is set to enter the market in earnest. Celltrion announced on the 18th (local time) that the ZYMFENTRA was successfully released throughout the United States.
ZYMFENTRA is the first product Celltrion obtained a new drug license from the US Food and Drug Administration (FDA) in October last year. It has been approved for patients with moderate to severe adult active ulcerative colitis (UC) and Crohn's disease (CD), and the recommended dose is 120mg per session every two weeks.
Wholesale price (WAC) of ZYMFENTRA was set at $ 6181.08 (8.24 million won) for two investments and four weeks. Celltrion has set the optimal price to operate an effective sales strategy in comprehensive consideration of ZYMFENTRA's new drug status, the price of competing drugs for inflammatory bowel disease (IBD), and the characteristics of the US pharmaceutical bio market.
ZYMFENTRA can receive patent protection up to 2040 if patents for the currently applied subcutaneous injection (SC) formulation and administration method are registered, enabling stable mid- to long-term profitability in the United States, the world's largest pharmaceutical market. Because ZYMFENTRA is SC-shaped, it is easy to self-administer at home in the United States, where medical accessibility is low.
According to IQVIA, a pharmaceutical market research firm, the IBD market that ZYMFENTRA focuses on amounts to 12.8 trillion won.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
